Skip to main content

Browse by Speciality Area

Browse by Product Type

All Products

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The continued shortage of the Haemophilus influenza type b (Hib) vaccine has not led to an increase in Haemophilus infections according to the MMWR.

Continued shortage for Hib vaccine

January 2, 2015

Reprints

Related Articles

Continued shortage for Hib vaccine

The continued shortage of the Haemophilus influenza type b (Hib) vaccine has not led to an increase in Haemophilus infections according to the MMWR. It has been a year since the CDC recommended deferring the fourth dose of the Hib vaccine in healthy children (at 12-15 months of age) because of a shortage due to contamination concerns in the manufacturing process. Merck & Co. now reports that mid-2009 is a realistic date for normal production. The CDC has undertaken national surveillance for Hib infections including 748 cases in children < 5 years old. Of these, only 6% were clearly identified as serotype b (the most invasive strain of Haemophilus), although serotyping information was missing in nearly 40% of cases. The CDC is concerned because antibody levels fall 12 months after vaccination in children. In the U.K., where the fourth booster was not initially recommended, Hib infections rebounded after 12-15 months. CDC is recommending vigilance on the part of pediatricians and also is emphasizing that state and hospital labs should perform serotyping on all Haemophilus infections.